SERPINA1 gene editing therapy (Editas Medicine)

N/A

Report date: 2025/11/19 10:17:05

Base Information

Drug NameSERPINA1 gene editing therapy (Editas Medicine)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionAlpha-1-antiproteinase modulators
TargetsAlpha-1-antiproteinase
Therapy Area/Indicationsalpha 1-Antitrypsin Deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEditas Medicine Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEditas Medicine Inc
Active IndicationsN/A
Inactive Indicationsalpha 1-Antitrypsin Deficiency

Other Information

ATC CodeN/A
Related LinksN/A